肿瘤免疫检查点PD-1/PD-L1抑制剂的中药活性成分研究进展

Research progress on active ingredients from traditional Chinese medicine as inhibitors of PD-1/PD-L1 of cancer immune checkpoint

肿瘤免疫治疗已成为新型的癌症治疗手段,有望彻底消除肿瘤。免疫检查点抑制剂,特别是程序性死亡受体-1(PD-1)和程序性死亡受体-配体1(PD-L1)抗体在多种实体瘤的治疗中取得很好的临床疗效,但是生物制剂存在免疫原性强、价格昂贵等缺点,因此,寻找免疫检查点小分子抑制剂成为未来肿瘤免疫疗法的新挑战。本文将综述近年发现的抑制PD-1/PD-L1表达的中药活性小分子及其对肿瘤免疫微环境的调控作用。

Tumor immunotherapy has become a new cancer treatment which has been expected to eliminate tumors.Immune checkpoint inhibitors,especially programmed death-1(PD-1)and programmed death-ligand 1(PD-L1)antibodies,have achieved significant clinical efficacy in the treatment of solid tumors.But biologics possess disadvantages such as strong immunogenicity and high cost.Therefore,the discovery of small molecule drugs as immune checkpoint inhibitors may overcome the shortcomings of biologics and become a new challenge for future tumor immunotherapy.The active small molecules from traditional Chinese medicine that inhibit the expression of PD-1/PD-L1 and their regulatory effects on the tumor immune microenvironment were reviewed in this paper.